-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
WuXi AppTec Content Team Editor Recently, Ribon Therapeutics announced that he has partnered with Boehringer Ingelheim Ingelheim) has reached an agreement
to acquire its preclinical CD38 program.
Boehringer Ingelheim aims to develop new therapies
that improve the lives of patients with immune and fibrotic diseases based on Ribon's CD38 project.
Boehringer Ingelheim's acquisition is a small molecule inhibitor designed to regulate intracellular and extracellular CD38 activity developed by Ribon using its proprietary BEACON+ platform, with the potential to
restore immune function in patients with a variety of diseases.
Under the terms of the agreement, Ribon will receive an undisclosed advance payment and will be eligible to receive future payments
related to preclinical, clinical, regulatory and commercial milestones.
Ribon Therapeutics noted in the press release that this protocol validates its BEACON+ platform
that targets NAD+ utilizing enzymes.
Ribon has developed methods
to identify and characterize substrates of these enzymes and analyze their underlying biological mechanisms.
Through these methods, Ribon was also able to identify biomarkers for patient screening and as early surrogate indicators of clinical response
.
The platform aims to develop effective, selective NAD+ utilization enzyme small molecule modulators and effectively assess their therapeutic potential
by combining novel biological insights, molecular expression profiles, cell biology, in vivo models, and genetic tools.
▲ Components of the BEACON+ platform (Image source: RibonTherapeutics official website)
In addition to the acquired CD38 project, Ribon's main drug candidates also include RBN-2397, a PARP7 inhibitor for the treatment of solid tumors, and RBN-3143
, a PARP14 inhibitor for the treatment of inflammation.
Ribon will continue to focus on the development of RBN-2397 and RBN-3143 while advancing other early pipelines
derived from its BEACON+ platform.
Dr.
Prakash Raman, President and CEO of Ribon Therapeutics, said: "We are delighted to enter into this agreement with Boehringer Ingelheim, which builds on the pioneering work of our BEACON+ platform and promises potential for patients with CD38 activity-related diseases.
First-in-class' treatment, thus significantly improving their prognosis
.
In addition, we believe that this agreement, along with RBN-2397 and RBN-3143, which we are evaluating in clinical trials, further validates our potential therapeutic options and capabilities
to discover and develop NAD+ utilization enzymes using the BEACON+ platform.
▲To learn more about the application of cutting-edge technologies in the biomedical industry, please long press and scan the QR code above to visit the "WuXi Live Room" to watch live discussions and wonderful replay references on related topics
[1] Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim.
Retrieved November 29, 2022, from https://ribontx.
com/ribon-therapeutics-announces-acquisition-of-pre-clinical-cd38-program-by-boehringer-ingelheim/
Disclaimer: WuXi AppTec's content team focuses on global biomedical health research progress
.
This article is for informational purposes only, and the views expressed in this article do not represent the position of WuXi AppTec, nor do they represent WuXi AppTec's support or disapproval of the views
expressed in the article.
This article is also not a treatment recommendation
.
For guidance on treatment options, go to a regular hospital
.
to acquire its preclinical CD38 program.
Boehringer Ingelheim aims to develop new therapies
that improve the lives of patients with immune and fibrotic diseases based on Ribon's CD38 project.
Boehringer Ingelheim's acquisition is a small molecule inhibitor designed to regulate intracellular and extracellular CD38 activity developed by Ribon using its proprietary BEACON+ platform, with the potential to
restore immune function in patients with a variety of diseases.
Under the terms of the agreement, Ribon will receive an undisclosed advance payment and will be eligible to receive future payments
related to preclinical, clinical, regulatory and commercial milestones.
Ribon Therapeutics noted in the press release that this protocol validates its BEACON+ platform
that targets NAD+ utilizing enzymes.
Ribon has developed methods
to identify and characterize substrates of these enzymes and analyze their underlying biological mechanisms.
Through these methods, Ribon was also able to identify biomarkers for patient screening and as early surrogate indicators of clinical response
.
The platform aims to develop effective, selective NAD+ utilization enzyme small molecule modulators and effectively assess their therapeutic potential
by combining novel biological insights, molecular expression profiles, cell biology, in vivo models, and genetic tools.
▲ Components of the BEACON+ platform (Image source: RibonTherapeutics official website)
In addition to the acquired CD38 project, Ribon's main drug candidates also include RBN-2397, a PARP7 inhibitor for the treatment of solid tumors, and RBN-3143
, a PARP14 inhibitor for the treatment of inflammation.
Ribon will continue to focus on the development of RBN-2397 and RBN-3143 while advancing other early pipelines
derived from its BEACON+ platform.
Dr.
Prakash Raman, President and CEO of Ribon Therapeutics, said: "We are delighted to enter into this agreement with Boehringer Ingelheim, which builds on the pioneering work of our BEACON+ platform and promises potential for patients with CD38 activity-related diseases.
First-in-class' treatment, thus significantly improving their prognosis
.
In addition, we believe that this agreement, along with RBN-2397 and RBN-3143, which we are evaluating in clinical trials, further validates our potential therapeutic options and capabilities
to discover and develop NAD+ utilization enzymes using the BEACON+ platform.
▲To learn more about the application of cutting-edge technologies in the biomedical industry, please long press and scan the QR code above to visit the "WuXi Live Room" to watch live discussions and wonderful replay references on related topics
[1] Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim.
Retrieved November 29, 2022, from https://ribontx.
com/ribon-therapeutics-announces-acquisition-of-pre-clinical-cd38-program-by-boehringer-ingelheim/
Disclaimer: WuXi AppTec's content team focuses on global biomedical health research progress
.
This article is for informational purposes only, and the views expressed in this article do not represent the position of WuXi AppTec, nor do they represent WuXi AppTec's support or disapproval of the views
expressed in the article.
This article is also not a treatment recommendation
.
For guidance on treatment options, go to a regular hospital
.
